Elisabet Aliagas

Elisabet Aliagas

Auto-generated profile, based on publicly available information

Elisabet Aliagas

Preclinical and experimental research in thoracic tumors (PRETT) group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Open access
PDF file
ELElise G. Lavoie
Elise G. Lavoie
BGBrian David Gulbransen
Brian David Gulbransen
MMMireia Martín-Satué
Mireia Martín-Satué
EAElisabet Aliagas
Elisabet Aliagas
KSKeith A. Sharkey
Keith A. Sharkey
Jean SévignyJean Sévigny
Jean Sévigny
Extracellular nucleotides and adenosine are biologically active molecules that bind members of the P2 and P1 receptor families, respectively. In the digestive system, these receptors modulate various functions, including salivary, gastric, and intestinal epithelial secretion and enteric neurotransmission. The availability of P1 and P2 ligands is modulated by ectonucleotidases, enzymes that hydrolyze extracellular nucleotides into nucleosides. Nucleoside triphosphate diphosphohydrolases (NTPDases) and ecto-5′-nucleotidase are the dominant ectonucleotidases at physiological pH. While there is some information about the localization of ecto-5′-nucleotidase and NTPDase1 and -2, the distribution of NTPDase3 in the digestive system is unknown. We examined the localization of these ectonucleotidases, with a focus on NTPDase3, in the gastrointestinal tract and salivary glands. NTPDase1, -2, and -3 are responsible for ecto-ATPase activity in these tissues. Semiquantitative RT-PCR, immunohistochemistry, and in situ enzyme activity revealed the presence of NTPDase3 in some epithelial cells in serous acini of salivary glands and mucous acini and duct cells of sublingual salivary glands, in cells from the stratified esophageal and forestomach epithelia, and in some enteroendocrine cells of the gastric antrum. Interestingly, NTPDase2 and ecto-5′-nucleotidase are coexpressed with NTPDase3 in salivary gland cells and stratified epithelia. In the colon, neurons express NTPDase3 and glial cells express NTPDase2. Ca2+ imaging experiments demonstrate that NTPDases regulate P2 receptor ligand availability in the enteric nervous system. In summary, the specific localization of NTPDase3 in the digestive system suggests functional roles of the enzyme, in association with NTPDase2 and ecto-5′-nucleotidase, in epithelial functions such as secretion and in enteric neurotransmission.

1 January 2014 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
EAElisabet Aliagas
Elisabet Aliagas
AVAugust Vidal
August Vidal
LTLaura Texidó
Laura Texidó
JPJordi Ponce
Jordi Ponce
ECEnric Condom
Enric Condom
MMMireia Martín-Satué
Mireia Martín-Satué
One of the strategies used by tumors to evade immunosurveillance is the accumulation of extracellular adenosine, which has immunosupressive and tumor promoting effects. The study of the mechanisms leading to adenosine formation at the tumor interstitium are therefore of great interest in oncology. The dominant pathway generating extracellular adenosine in tumors is the dephosphorylation of ATP by ecto-nucleotidases. Two of these enzymes acting sequentially, CD39 and CD73, efficiently hydrolyze extracellular ATP to adenosine. They have been found to play a crucial role in a variety of tumors, but there were no data concerning endometrial cancer, the most frequent of the invasive tumors of the female genital tract. The aim of the present work is to study the expression of CD39 and CD73 in human endometrial cancer. We have analyzed protein and gene expression, as well as enzyme activity, in type I endometrioid adenocarcinomas and type II serous adenocarcinomas and their nonpathological endometrial counterparts. High levels of both enzymes were found in tumor samples, with significantly increased expression of CD39 in type II serous tumors, which also coincided with the higher tumor grade. Our results reinforce the involvement of the adenosinergic system in cancer, emphasizing the relevance of ecto-nucleotidases as emerging therapeutic targets in oncology.

11 May 2010 in Histochemistry and Cell Biology
Verified
Journal Article
Closed access
PDF file
MMMireia Martín-Satué
Mireia Martín-Satué
ELElise G. Lavoie
Elise G. Lavoie
MFMichel Fausther
Michel Fausther
JLJoanna Lecka
Joanna Lecka
EAElisabet Aliagas
Elisabet Aliagas
Jean SévignyJean Sévigny
Jean Sévigny

25 February 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
AAAnia Alay
Ania Alay
DCDavid Cordero
David Cordero
SHSara Hijazo-Pechero
Sara Hijazo-Pechero
EAElisabet Aliagas
Elisabet Aliagas
ALAdriana Lopez-Doriga
Adriana Lopez-Doriga
XSXavier Solé
Xavier Solé
Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive neoplasia affecting the lung mesothelium. Immune checkpoint inhibitors (ICI) in MPM have not been extremely successful, likely due to poor identification of suitable candidate patients for the therapy. We aimed to identify cellular immune fractions associated with clinical outcome and classify patients with MPM based on their immune contexture. For each defined group, we sought for molecular specificities that could help further define our MPM classification at the genomic and transcriptomic level, as well as identify differential therapeutic strategies based on transcriptional signatures predictive of drug response. Methods: The abundance of 20 immune cell fractions in 516 MPM samples from 7 gene expression datasets was inferred using gene set variation analysis. Identification of clinically relevant fractions was performed with Cox proportional-hazards models adjusted for age, stage, sex, and tumor histology. Immune-based groups were defined based on the identified fractions. Results: T-helper 2 (TH2) and cytotoxic T (TC) cells were found to be consistently associated with overall survival. Three immune clusters (IG) were subsequently defined based on TH2 and TC immune infiltration levels: IG1 (54.5%) was characterized by high TH2 and low TC levels, IG2 (37%) had either low or high levels of both fractions, and IG3 (8.5%) was defined by low TH2 and high TC levels. IG1 and IG3 groups were associated with worse and better overall survival, respectively. While no differential genomic alterations were identified among immune groups, at the transcriptional level, IG1 samples showed upregulation of proliferation signatures, while IG3 samples presented upregulation of immune and inflammation-related pathways. Finally, the integration of gene expression with functional signatures of drug response showed that IG3 patients might be more likely to respond to ICI. Conclusions: This study identifies a novel immune-based signature with potential clinical relevance based on TH2 and TC levels, unveiling a fraction of patients with MPM with better prognosis and who might benefit from immune-based therapies. Molecular specificities of the different groups might be used to tailor specific potential therapies in the future.

6 December 2012 in Purinergic Signalling
Verified
Journal Article
Closed access
PDF file
EAElisabet Aliagas
Elisabet Aliagas
AVAugust Vidal
August Vidal
BTBenjamín Torrejón-Escribano
Benjamín Torrejón-Escribano
MTMaria del Rosario Taco
Maria del Rosario Taco
JPJordi Ponce
Jordi Ponce
MMMireia Martín-Satué
Mireia Martín-Satué

16 June 2013 in Purinergic Signalling
Verified
Journal Article
Closed access
PDF file
EAElisabet Aliagas
Elisabet Aliagas
IVIzaskun Villar-Menéndez
Izaskun Villar-Menéndez
Jean SévignyJean Sévigny
Jean Sévigny
MRMercedes Roca
Mercedes Roca
MRMiriam Romeu
Miriam Romeu
MBMarta Barrachina
Marta Barrachina